Psychophysiologic Symptom Relief Therapy (PSRT) for Post-acute Sequelae of COVID-19.

ABSTRACT:

Objective

To determine if psychophysiologic symptom relief therapy (PSRT) will reduce symptom burden in patients suffering from post-acute sequelae of COVID-19 (PASC) who had mild/moderate acute COVID-19 disease without objective evidence of organ injury.

Patients and methods

Twenty-three adults under the age of 60 with PASC for at least 12 weeks following COVID-19 infection were enrolled in an interventional cohort study conducted via virtual platform between May 18, 2021 and August 7, 2022. Participants received PSRT during a 13 week (approximately 44 hour) course. Participants were administered validated questionnaires at baseline and at 4, 8, and 13 weeks. The primary outcome was change in somatic symptoms from baseline, measured using the Somatic Symptom Scale-8 (SSS-8)

SUBMITTER: Donnino M 

PROVIDER: S-EPMC10196153 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature